Tags

Type your tag names separated by a space and hit enter

Immunogenicity and safety of a monovalent vaccine for the 2009 pandemic influenza virus A (H1N1) in children and adolescents.
Vaccine. 2010 Aug 16; 28(36):5864-70.V

Abstract

The 2009 pandemic influenza A (H1N1) has caused significant morbidity and mortality around the world. Safety and immunogenicity studies of 2009 pandemic influenza A (H1N1) virus in children and adolescents are limited. In this prospective, open-label study, 2 doses of a monovalent, unadjuvanted, inactivated, split-virus 2009 pandemic influenza virus A (H1N1) vaccine (AdimFlu-S) were administered to 183 healthy children and adolescents aged 1-17 years. Adverse reactions were assessed, and hemagglutination inhibition antibody titers were determined. Three weeks after the first dose, 36.2% of children aged 1-2 years, 52.5% of children aged 3-5 years, 56.7% of children aged 6-9 years, and 90.3% of adolescents aged 10-17 years generated protective antibodies. A second vaccination given 3 weeks later induced protective antibodies in 89.4% of all age groups. No severe adverse effects were found 6 weeks after vaccination.

Authors+Show Affiliations

Department of Pediatrics, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20600484

Citation

Lu, Chun-Yi, et al. "Immunogenicity and Safety of a Monovalent Vaccine for the 2009 Pandemic Influenza Virus a (H1N1) in Children and Adolescents." Vaccine, vol. 28, no. 36, 2010, pp. 5864-70.
Lu CY, Shao PL, Chang LY, et al. Immunogenicity and safety of a monovalent vaccine for the 2009 pandemic influenza virus A (H1N1) in children and adolescents. Vaccine. 2010;28(36):5864-70.
Lu, C. Y., Shao, P. L., Chang, L. Y., Huang, Y. C., Chiu, C. H., Hsieh, Y. C., Lin, T. Y., & Huang, L. M. (2010). Immunogenicity and safety of a monovalent vaccine for the 2009 pandemic influenza virus A (H1N1) in children and adolescents. Vaccine, 28(36), 5864-70. https://doi.org/10.1016/j.vaccine.2010.06.059
Lu CY, et al. Immunogenicity and Safety of a Monovalent Vaccine for the 2009 Pandemic Influenza Virus a (H1N1) in Children and Adolescents. Vaccine. 2010 Aug 16;28(36):5864-70. PubMed PMID: 20600484.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Immunogenicity and safety of a monovalent vaccine for the 2009 pandemic influenza virus A (H1N1) in children and adolescents. AU - Lu,Chun-Yi, AU - Shao,Pei-Lan, AU - Chang,Luan-Yin, AU - Huang,Yhu-Chering, AU - Chiu,Cheng-Hsun, AU - Hsieh,Yu-Chia, AU - Lin,Tzou-Yien, AU - Huang,Li-Min, Y1 - 2010/07/13/ PY - 2010/02/04/received PY - 2010/06/04/revised PY - 2010/06/18/accepted PY - 2010/7/6/entrez PY - 2010/7/6/pubmed PY - 2010/11/16/medline SP - 5864 EP - 70 JF - Vaccine JO - Vaccine VL - 28 IS - 36 N2 - The 2009 pandemic influenza A (H1N1) has caused significant morbidity and mortality around the world. Safety and immunogenicity studies of 2009 pandemic influenza A (H1N1) virus in children and adolescents are limited. In this prospective, open-label study, 2 doses of a monovalent, unadjuvanted, inactivated, split-virus 2009 pandemic influenza virus A (H1N1) vaccine (AdimFlu-S) were administered to 183 healthy children and adolescents aged 1-17 years. Adverse reactions were assessed, and hemagglutination inhibition antibody titers were determined. Three weeks after the first dose, 36.2% of children aged 1-2 years, 52.5% of children aged 3-5 years, 56.7% of children aged 6-9 years, and 90.3% of adolescents aged 10-17 years generated protective antibodies. A second vaccination given 3 weeks later induced protective antibodies in 89.4% of all age groups. No severe adverse effects were found 6 weeks after vaccination. SN - 1873-2518 UR - https://www.unboundmedicine.com/medline/citation/20600484/Immunogenicity_and_safety_of_a_monovalent_vaccine_for_the_2009_pandemic_influenza_virus_A__H1N1__in_children_and_adolescents_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(10)00881-9 DB - PRIME DP - Unbound Medicine ER -